Protalix Of Israel Gets U.S. Clearance To Market Gaucher’s Drug
This article was originally published in PharmAsia News
Executive Summary
Israel’s Protalix Biotherapeutics won U.S. FDA approval to market its Elelyso (taliglucerase) drug for treating Gaucher’s disease, developed by Pfizer.